You are here: Industry Insights > Roche

News List

Roche's I-O drug Tecentriq picks up key first-in-class breast cancer nod! fiercepharma
March 12, 2019
In a first for the immuno-oncology field, Roche’s Tecentriq has a big new approval in breast cancer.
Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer biospectrumasia
March 11, 2019
Roche's Genentech unit on Friday announced that the FDA granted accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for use in adults with PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast ca
Biogen to buy gene therapy firm Nightstar Therapeutics for $800m pharmaceutical-technology
March 05, 2019
US-based biotechnology company Biogen has signed an agreement to acquire UK-based gene therapy firm Nightstar Therapeutics for a cash consideration of $800m.
Immatics, Roche ally to trial Tecentriq with cell therapy fiercebiotech
February 27, 2019
Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors....
Roche to acquire gene therapy specialist Spark Therapeutics for $4.8bn pharmaceutical-technology
February 26, 2019
Roche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy company Spark Therapeutics for $114.50 per share....
Roche nabs coveted FDA ‘real-time review’ for key Kadcyla move into early breast cancer fiercepharma
February 24, 2019
Two months after Roche unveiled clinical trial data that could help bring its breast cancer drug Kadcyla to early-stage patients, the company has won a speedy FDA review.
Swayed by discounts, NICE finally backs Roche's Perjeta for postsurgery breast cancer fiercepharma
February 24, 2019
Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer in England.
Will mutant strains hurt prospects for Roche's flu-fighting newcomer Xofluza? fiercepharma
February 24, 2019
Xofluza, Roche’s bid to replace sales from the now-generic Tamiflu, has yet to catch on in the U.S., and new reports of viral resistance in Japan won’t help the drug’s case.
Two new cancer Priority Reviews for Roche pharmaphorum
February 20, 2019
Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polatuzumab vedotin.
NICE recommends Roche’s breast cancer drug pertuzumab pharmaceutical-technology
February 19, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s Perjeta (pertuzumab) by the National Health Service (NHS) to treat early HER2-positive breast cancer, which has spread to lymph nodes.....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page